CClinicalTrials.gg
CompletedNCT07564037Updated May 7, 2026

Nebulized Dexmedetomidine, Ketamine, or Midazolam in Children Undergoing Adenotonsillectomy

An interventional study of Group K:nebulized ketamine group and Group D:dexmedetomidine group in Dexmedetomidine, Adenotonsillectomy and Midazolam, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Nov 2024, registered Apr 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
3 Years to 7 Years
Sex
All
01

Study summary

The aim of this study is to compare between nebulized dexmedetomidine, ketamine, or midazolam for premedication in children undergoing adenotonsillectomy.

Read the detailed description

The aim of this study is to compare between nebulized dexmedetomidine, ketamine, or midazolam for premedication in children undergoing adenotonsillectomy.

Primary outcome:

  • A five-point sedation score on arrival in the operating room 30 min after drug administration.

Secondary outcomes:

  • Parental separation anxiety scale.
  • Medication and mask acceptance scales.
  • Hemodynamic variables.
  • Recovery time.
  • Postoperative face, legs, activity, cry, and consolability (FLACC) scale.
  • Emergence Agitation scale.
  • Adverse effects.
02

Conditions studied

  • Dexmedetomidine
  • Adenotonsillectomy
  • Midazolam
  • Children

Keywords

  • Midazolam
  • Nebulized
  • Dexmedetomidine
  • Adenotonsillectomy
  • Children
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children aged between 3-7 years.
  • Both sexes.
  • American society of anesthesiologists (ASA) physical status (I-II).
  • Children undergoing adenotonsillectomy.

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergy to the study drugs.
  • Significant organ dysfunction.
  • Cardiac dysrhythmia.
  • Congenital heart disease.
  • Use of psychotropic medication, and mental retardation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Group K :nebulized ketamine group

    Group K: Patients will receive nebulized ketamine 2 mg kg -1

    Drug: Group K:nebulized ketamine group

  • Experimental
    Group D: dexmedetomidine group

    Group D: Patients will receive dexmedetomidine 2 mcg kg -1

    Drug: Group D:dexmedetomidine group

  • Experimental
    Group M:midazolam group

    (Group M): Patients will receive midazolam 0.2 mg kg -1

    Drug: Group M: midazolam group

Interventions

  • DrugGroup K:nebulized ketamine group

    Patients will receive nebulized ketamine 2 mg kg -1

  • DrugGroup D:dexmedetomidine group

    Patients will receive dexmedetomidine 2 mcg kg -1

  • DrugGroup M: midazolam group

    Patients will receive midazolam 0.2 mg kg -1

06

What researchers measure

Primary outcomes

  1. A five-point sedation score on arrival in the operating room

    Sedation level will be assessed at the same time points mentioned above using a five-point sedation scale score as follows: 1= agitated, 2= alert, 3= calm, 4= drowsy, and 5=asleep . A score ≥ 3 will be considered as acceptable sedation.

    Time frame: 30 min after drug administration

Secondary outcomes

  1. Parental separation anxiety scale

    parental separation will be assessed by a four-point parental separation anxiety scale (PSAS) as follows: 1= easy separation, 2= whimpers, but is easily reassured, not clinging, 3= cries and cannot be easily reassured, but not clinging to parents, and 4= crying and clinging to parents. PSAS scores of 1 and 2 signified acceptable separation whereas scores of 3 and 4 will be classified as difficult separation .

    Time frame: 2 hours

07

Study locations

1 site
  • Tanta University
    Tanta, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — It will be available when it needed

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07564037
Lead sponsor
Tanta University
Responsible party
Mohamed Mostafa Mohamed Abd Elfatah Elrefaie (Resident in Anesthesiology, Surgical ICU and Pain Medicine, Tanta University) — Principal investigator
First posted
May 4, 2026
Start date
Nov 30, 2024
Primary completion
Nov 30, 2025
Completion
Dec 30, 2025
Last update
May 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion